Cystic fibrosis treatment begins trials

Israel’s SpliSense (see here previously) has begun a first Phase 1/2 human trial of its SPL84 treatment for a specific genetic mutation that causes cystic fibrosis. SpliSense utilizes proprietary RNA therapies called ASOs (antisense oligonucleotides) to correct mutations.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *